Gut microbiota of the intestine

The **gut microbiota** refers to the diverse community of microorganisms—including bacteria from phyla such as Firmicutes and Bacteroidetes—that inhabit the human gastrointestinal tract. This ecosystem plays essential roles in digestion through fermentation processes that yield metabolites like short-chain fatty acids important for host energy balance. The gut microbiota also synthesizes vitamins unavailable from diet alone and interacts with host immune cells to regulate inflammation and maintain mucosal integrity. It communicates bidirectionally with other organ systems—most notably forming part of the “gut-brain axis”—and influences neurological health through metabolite signaling pathways. Alterations (“dysbiosis”) are implicated in a range of diseases including obesity/metabolic syndrome, type 2 diabetes, neuropsychiatric disorders such as depression/anxiety via modulation along kynurenine pathway metabolites,[2] neurodegenerative diseases,[3] cardiovascular disease,[3] chronic inflammatory states,[1] among others. While not a classical molecular target like an enzyme or receptor—and thus not strictly fitting standard drug-target definitions—the intestinal microflora is increasingly considered a therapeutic target due to its central role mediating drug metabolism/effects (“pharmacomicrobiomics”), influencing patient response variability,[8] and being amenable to intervention using probiotics/prebiotics/dietary changes.[6] However, because it is not a single molecule/protein/receptor but rather an ecological system comprising thousands of species interacting dynamically with each other and their host environment—and because “Bacterial microflora” is an outdated term replaced by “microbiota”/“microbiome”—this entry should be flagged as non-standard/incomplete per structured database conventions.[6]

Other names

Intestinal microfloraGut microbiomeHuman gut microbiotaIntestinal microbiota

Drugs or interventions targeting this “target” act by modifying the composition or activity of microbial communities—either increasing beneficial bacteria through probiotics/prebiotics or reducing harmful taxa. Mechanisms include modulation of metabolite production (such as SCFAs), reduction in pro-inflammatory signaling, restoration of barrier function, and alteration in neurotransmitter levels via the gut-brain axis.[1][2][4]